Loading...

About us

SYN INNOVATION LABORATORIES SA

It is based in Attica, Greece and is a societe anonyme importing and marketing pharmaceutical and radiopharmaceutical products, medical equipment, biotechnology and special nutritional products, with the aim of diagnosing and treating patients with cancer or rare diseases. By supplying hospitals and diagnostic centers with pharmaceutical products used in diagnostic imaging (MRI, CT, Cath Lab, Digital Solutions) as well as in invasive cardiology and radiology, we have obtained a clear and
in-depth picture of the market and its operating conditions

History timeline

Collaboration with GUERBET

By collaborating with Guerbet, which is a pioneer in the field of contrast media, SYN provides to Greece a comprehensive range of imaging products

2015
2017

Collaboration with Naos

The company expanded its activities to the cosmetics market through pharmacies, representing Naos, a well-known French dermocosmetics company

Collaboration with NESTLE

Agreement with Nestle, the leader in the field of nutritional science, to distribute foods for special medical purposes in Greece

2018
2019

Medical equipment to supply the Greek market

Distribution agreements with internationally recognized manufacturers of medical devices, to ensure the supply of innovative medical equipment to the Greek market

New high-tech production unit

2021 the construction of the high-tech production unit for the production of radiopharmaceuticals in Agios Theodoros, Corinth, was completed. The purpose of this production unit is to supply hospitals and other diagnostic units with high value-added material used in PET-CT Scan diagnostic tests. The main usefulness of these diagnostic tests is, the diagnosis of cancer in very early forms as well as brain diseases, degenerative diseases etc.

2021

To achieve its goals and strategy, the company seeks to:

  • Target niche therapeutic products that require intense and flexible activation to promote and support sales
  • Cover South East Europe in terms of marketing authorizations, sales prices and pharmacovigilance
  • Access health stakeholders in the target markets (Greece, Cyprus, Bulgaria, Albania and Kosovo)
  • Establish new and mutually beneficial strategic alliances with various companies and partners
  • Full exploit the synergies that result from the relationship between pharmacists – doctors – patients – users
  • Implement top quality systems and processes by establishing, monitoring and evaluating targets and objectives on quality and acknowledging all interested parties and their requirements
  • Continuously training aiming at constant improvement
Skip to content